Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Susu Xiao'er Zhike is a Traditional Chinese Medicine (TCM) granule formulation developed by The First Teaching Hospital of Tianjin University of TCM. It is specifically indicated for the treatment of cough caused by the common cold, particularly targeting "wind-cold cough syndrome" in pediatric patients. As a multi-ingredient herbal preparation, it is designed to alleviate respiratory symptoms, shorten the course of the illness, and improve overall recovery in children. The drug is currently being evaluated in Phase II clinical trials in China to establish its efficacy and safety profile for this specific indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Susu Xiao'er Zhike.